Outcomes of adalimumab therapy in refractory punctate inner choroidopathy and multifocal choroiditis.

Or ShmueliRadgonde Amer

Published in: Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie (2022)

Adalimumab therapy for refractory PIC/MFC enabled a significant steroid-sparing effect, decreased disease flares, and preserved vision over a mean follow-up of 17.8 months.

Keyphrases

rheumatoid arthritis
juvenile idiopathic arthritis
hidradenitis suppurativa
ulcerative colitis
disease activity
bone marrow
skeletal muscle
glycemic control